Crossmark

Guidelines for reporting artificial intelligence studies in medicines, pharmacotherapy, and pharmaceutical services: MedinAI development, validation and statement

Crossref DOI link: https://doi.org/10.1007/s11096-025-01905-3

Published Online: 2025-04-09

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bottacin, Wallace Entringer https://orcid.org/0000-0001-7721-5876
de Souza, Thais Teles https://orcid.org/0000-0002-6820-4259
Reis, Walleri Christini Torelli

Melchiors, Ana Carolina https://orcid.org/0000-0001-6911-4792
Funding

Funding for this research was provided by:

PROPESQ/PRPG/UFPB (PVG 13392-2020)
License Information

Text and Data Mining valid from 2025-04-09

Version of Record valid from 2025-04-09
More Information

Article History

Received: 15 November 2024

Accepted: 13 March 2025

First Online: 9 April 2025

Conflicts of interest

: The author declares no conflicts of interest related to the development and publication of this work.

Document is current

Any future updates will be listed below